Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...

Incyte Corporation (NASDAQ:INCY), a biopharmaceutical company specializing in oncology and dermatology, finds itself at a critical juncture as it navigates the impending loss of patent protection ...

Incyte Corporation (NASDAQ:INCY), a biopharmaceutical company specializing in oncology and dermatology, finds itself at a critical juncture as it navigates the impending loss of patent protection for ...

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...

Learn about the common myths and misconceptions about hidradenitis suppurativa (HS) and why it is often misdiagnosed.